Bioventus (BVS) Gross Profit (2020 - 2026)

Bioventus (BVS) has 7 years of Gross Profit data on file, last reported at $90.8 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 9.29% year-over-year to $90.8 million; the trailing twelve-month figure through Mar 2026 stood at $395.9 million (up 3.39% YoY), and the FY2025 full-year result was $388.2 million, changed 0.02% from the prior year.
• Gross Profit for Q1 2026 stood at $90.8 million, down from $108.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $108.8 million in Q4 2025 and bottomed at $73.9 million in Q2 2023.
• The 5-year median for Gross Profit is $89.1 million (2023), against an average of $89.8 million.
• Peak annual rise in Gross Profit reached 27.11% in 2022, while the deepest fall reached 15.47% in 2022.
• A 5-year view of Gross Profit shows it stood at $74.2 million in 2022, then gained by 16.33% to $86.3 million in 2023, then gained by 18.95% to $102.7 million in 2024, then climbed by 5.97% to $108.8 million in 2025, then fell by 16.56% to $90.8 million in 2026.
• The last three Gross Profit figures came in at $90.8 million (Q1 2026), $108.8 million (Q4 2025), and $94.2 million (Q3 2025), per Business Quant data.

Peer Comparison